IFNL3 and fatty liver disease: Response to interferon-based therapy has been shown to depend on interleukin 28B (IL28B) gene polymorphism, HCV genotype, viral load, ethnicity, age, hepatic fibrosis, hepatic steatosis, and drug adherence [8,9,10,11].